Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain / Estudio en el mundo real sobre patrones de prueba de inestabilidad de microsatélites y deficiencia de reparación de desajustes en pacientes con cáncer colorrectal metastásico en España
Clin. transl. oncol. (Print)
; 26(4): 864-871, Abr. 2024. tab
Article
in En
| IBECS
| ID: ibc-VR-49
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
Purpose:
Clinical practice guidelines recommend that all patients with metastatic colorectal cancer (mCRC) should be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H). We aimed to describe the dMMR/MSI-H testing practice in patients with mCRC in Spanish centers.Methods:
Multicenter, observational retrospective study that included patients newly diagnosed with mCRC or who progressed to a metastatic stage from early/localized stages.Results:
Three hundred patients were included in the study from May 2020 through May 2021, with a median age of 68 years, and two hundred twenty-five (75%) had stage IV disease at initial diagnosis; two hundred eighty-four patients received first-line treatment, and dMMR/MSI-H testing was performed in two hundred fifty-one (84%) patients. The results of the dMMR/MSI-H tests were available in 61 (24%) of 251 patients before the diagnosis of metastatic disease and in 191 (81%) of 236 evaluable patients for this outcome before the initiation of first-line treatment. Among the 244 patients who were tested for dMMR/MSI-H with IHC or PCR, 14 (6%) were MMR deficient. The most frequent type of first-line treatment was the combination of chemotherapy and biological agent, that was received by 71% and 50% of patients with MMR proficient and deficient tumors, respectively, followed by chemotherapy alone, received in over 20% of patients in each subgroup. Only 29% of dMMR/MSI-H tumors received first-line immunotherapy.Conclusion:
Our study suggests that a high proportion of patients with mCRC are currently tested for dMMR/MSI-H in tertiary hospitals across Spain. However, there is still room for improvement until universal testing is achieved.(AU)Key words
Full text:
1
Collection:
06-national
/
ES
Database:
IBECS
Main subject:
Arthroplasty, Replacement, Hip
/
Ophthalmology
/
Parents
/
Appendectomy
/
Appendicitis
/
Appendix
/
Physical Examination
/
Postoperative Complications
/
Postoperative Period
/
Arthritis
Type of study:
Diagnostic_studies
/
Etiology_studies
/
Evaluation_studies
/
Incidence_studies
/
Observational_studies
/
Prevalence_studies
/
Prognostic_studies
/
Qualitative_research
/
Risk_factors_studies
/
Screening_studies
Aspects:
Implementation_research
Limits:
Humans
/
Male
/
Female
/
Aged
/
Child
/
Adolescent
/
Adult
/
Animals
/
Child, preschool
/
Pregnancy
Country/Region as subject:
Europa
Language:
Es
/
En
Journal:
An. pediatr. (2003. Ed. impr.)
/
Asclepio
/
Cir. pediátr
/
Clin. transl. oncol. (Print)
/
Int. microbiol
/
Nutr. hosp
/
Radiología (Madr., Ed. impr.)
/
Reumatol. clín. (Barc.)
/
Rev. esp. anestesiol. reanim
/
Rev. esp. cir. ortop. traumatol. (Ed. impr.)
Year:
2023
/
2022
/
2024
/
2021
Document type:
Article